Vertex to acquire rights to cystic fibrosis treatment for $1.6m
US-based Vertex Pharmaceuticals has agreed to acquire a potential treatment for cystic fibrosis from Concert Pharmaceuticals, also in the US, for $160 million.
Under the agreement, Vertex will acquire the US development and commercial rights for CTP-656 for $160 million.
CTP-656 is an “investigational cystic fibrosis transmembrane conductance regulator potentiator”.
The announcement was made on Monday, March 6.
If CTP-656 is approved as part of a combination regimen to treat cystic fibrosis, "Concert could receive up to an additional $90 million in milestones, based on regulatory approval in the US and reimbursement in the UK, Germany or France".
Roger Tung, president and CEO of Concert, said: “With Vertex's clinical and commercial expertise in cystic fibrosis, this agreement provides the optimal pathway to rapidly advance the development of CTP-656 for the benefit of cystic fibrosis patients.”
He added that the financial strength provided to Concert by this agreement will allow the company to advance another treatment, called CTP-543, into “pivotal testing”.
CTP-543 is a treatment for baldness.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk